Including three members of the faculty of Dartmouth Medical College.

AAAS elevates Dartmouth professors to rank of Fellow The American Association for the Advancement of Technology has elevated four Dartmouth professors to the rank of Fellow, including three members of the faculty of Dartmouth Medical College. Medical School faculty members Charles K. Barlowe, PhD, Ta-Yuan Chang, PhD, and William T suomi-info.net . Wickner, MD, join Dartmouth biologist C. In December Robertson McClung among the 504 fresh Fellows named, 2010, joining a field of eight additional Dartmouth researchers to have gained the distinction. Barlowe, professor of biochemistry, was known for ‘distinguished contributions to the field of proteins and lipid trafficking, particularly for elucidating molecular mechanisms of vesicular transport between endoplasmic Golgi and reticulum complexes.’ Chang, professor and chair of biochemistry, was identified for ‘distinguished contributions to our understanding of cholesterol fat burning capacity and its own role in individual disease.’ Wickner, professor of biochemistry, was acknowledged for his ‘singular initiatives in the isolation and characterization of the bacterial secretory protein translocation complex and the complete machinery for yeast vacuole fusion.’ Related StoriesUnderstanding how schizophrenia impacts workings of the brainGriffith University uncovers initial 3-D picture of protein linked to cancer spreadMyriad RBM's DiscoveryMAP system identifies protein biomarkers linked to CV events in diabetes sufferers’Dartmouth is definitely a location where important study occurs,’ noted Dartmouth Medical School Dean Wiley ‘Chip’ Souba, MD.

What do you consider can be carried out to supply consumers with reasonably priced drugs and keep cash flowing to R&D simultaneously? Photo by klynslis.. Last Tuesday, a US House of Representatives subcommittee held a hearing in the deals pharmaceutical companies strike with each other to delay generic drugs from reaching the market. In these deals, a company desperate to continue making a benefit from its brand-name drug pays another firm to refrain from selling a generic version. According to the Home subcommittee hearing, such offers made between 1993 and 2008 have cost US customers at least $12 billion yearly.